Loading
ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1).
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Vemurafenib, Trametinib and Dabrafenib.
In plain words · ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression.
No product in this corpus aims at ATXN1L yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA ATXN1L: RNA low tissue specificity; no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ATXN1L tissue; Open Targets ENSG00000224470 associations
First described 2004. Earliest sequence paper UniProt cites for the protein: Martin et al, Nature, 2004, "The sequence and analysis of duplication-rich human chromosome 16". Source.
Sources: HGNC HGNC:33279 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P0C7T5 (protein name, function text, keywords and locations (REST API)); CIViC gene ATXN1L (2 evidence items, 0 assertions, 1 variants; diseases: Melanoma, Pancreatic Cancer (GraphQL API, CC0))
Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1). In concert with CIC and ATXN1, involved in brain development. Location: Nucleus; Cell projection, dendrite (UniProt). Locus 16q22.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ATXN1L" OR ABSTRACT:"ATXN1L" OR TITLE:"ataxin 1 like" OR ABSTRACT:"ataxin 1 like" OR TITLE:"Ataxin-1-like" OR ABSTRACT:"Ataxin-1-like" OR TITLE:"BOAT1" OR ABSTRACT:"BOAT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATXN1L, not a curated reading list.